Form 4: Anteris Director Moss Receives Equity Grant

Anteris Technologies Global Corp. Director Gregory S. Moss was granted 66,563 Restricted Stock Units, aligning his interests with shareholders.

Summary

• Gregory S. Moss, a Director of Anteris Technologies Global Corp. (AVR), acquired 66,563 Restricted Stock Units (RSUs) on December 3, 2025.
• The first grant consists of 52,742 RSUs, which will vest in three approximately equal annual installments on June 7, 2026, June 7, 2027, and June 7, 2028, contingent on continued service.
• The second grant comprises 13,821 RSUs, vesting on the earlier of December 3, 2026 (first anniversary of grant date) or the date of the next annual stockholders meeting, also subject to continued service.
• Each RSU represents the right to receive one share of common stock.
• The transaction price for these RSUs was $0, which is typical for equity grants.

Sentiment

Score: 6

Explanation: Slightly positive due to the alignment of director interests with shareholders through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grant of Restricted Stock Units to Director Gregory S. Moss aligns his long-term interests with those of the company's shareholders.
• Equity-based compensation incentivizes management and directors to contribute to the company's sustained growth and performance.

Future Outlook

The vesting schedules for the RSUs indicate an expectation of continued service from Director Gregory S. Moss through the respective vesting dates, suggesting a commitment to long-term engagement with Anteris Technologies Global Corp.

Industry Context

Equity grants, such as Restricted Stock Units, are a standard component of executive and director compensation packages across various industries, particularly in technology and biotechnology sectors, to attract, retain, and motivate key personnel. This practice is consistent with broader industry trends in corporate governance and compensation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a common practice across publicly traded companies, including those in the medical technology and biotechnology sectors like Anteris Technologies.
• Vesting schedules tied to continued service, such as the three-year annual installments for 52,742 RSUs and the one-year or next annual meeting vesting for 13,821 RSUs, are typical mechanisms designed to promote long-term commitment and align director interests with shareholder value creation.
• Companies like Medtronic, Edwards Lifesciences, and Boston Scientific frequently utilize similar equity-based incentives for their non-employee directors and executives to foster retention and performance.

Stakeholder Impact

• Shareholders: Potential positive impact through better alignment of director incentives with long-term company performance and shareholder value creation.

Next Steps

• Vesting of 52,742 RSUs in three approximately equal annual installments on June 7, 2026, 2027, and 2028.
• Vesting of 13,821 RSUs on the earlier of December 3, 2026, or the date of the next annual stockholders meeting.

Key Dates

Recommendation

A Form 4 filing detailing a routine equity grant to a director is generally not a primary driver for a 'buy' or 'sell' recommendation. It indicates standard corporate compensation practices and alignment of interests, which is a neutral to slightly positive factor, but insufficient on its own to warrant a strong investment action. Investors should consider broader financial performance, strategic initiatives, and market conditions.

Keywords

Anteris Technologies, AVR, Gregory S. Moss, Director, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, SEC Form 4, Corporate Governance, Stock Grant